生物技术与制药领域的最新动态
Analyzing recovery setups for Agilent Technologies Inc. investors - Market Trend Report & AI Optimized Trading Strategy Guides - newser.com
3 Reasons to Sell ILMN and 1 Stock to Buy Instead - Finviz
What Thermo Fisher Scientific (TMO)'s FDA Clearance for EXENT System Means for Shareholders - simplywall.st
Roche: Data for Breast Cancer Drug Candidate Giredestrant Support Potential Differentiated Status - Morningstar Canada
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Finviz
Lone Star, Altaris, One Rock Said Among Bidders for Lonza Assets - Bloomberg.com
Freenome and Roche partner on cancer screening technology for ex-US markets - Medical Device Network
Creative Planning Grows Stock Position in Agilent Technologies, Inc. $A - MarketBeat
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Agilent Technologies Inc. stock outlook for YEAR - 2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma - Yahoo Finance
Is Agilent Technologies Inc. (AG8) stock prepared for digital transition - Weekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Tackling antimicrobial resistance, one genome at a time - Illumina
Agilent to Participate in Citi’s 2025 Global Healthcare Conference - Business Wire
Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs - citybiz
Agilent Wants Justices To Eye Invalidation Of CRISPR Patents - Law360
Roche Had A Positive Cancer Study — And Its Rival Flew 130% - Investor's Business Daily
10x Genomics at Wolfe Research Healthcare: Navigating Challenges and Opportunities - Investing.com
Thermo Fisher targets early-stage CGT bottlenecks with new Philadelphia hub - R&D World
Roche pill notches win in early breast cancer - BioPharma Dive